Company Profile
RenovoRx Stock Price, News & Catalysts
- Ticker:
- RNXT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.20 USD (-14.29%)
Close
Last updated: August 17, 2026
41.1M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, RNXT closed down 14.3% at $1.20. No new same-company headline was identified in the current news window.
Company overview
Targeted Intra-Arterial Drug Delivery
RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure. Its Trans-Arterial Micro-Perfusion platform combines a device with a targeted treatment protocol.
RenovoCath
RenovoCath is an FDA-cleared dual-balloon infusion catheter designed to isolate a vascular segment and deliver therapy through the arterial wall. The device is commercially available to cancer centers as a stand-alone delivery product.
Broader Solid-Tumor Use
Although RenovoCath was initially used primarily in pancreatic cancer, physicians have begun applying the device in other solid tumors, including sarcoma. This creates a potential route to expand utilization beyond the lead clinical indication.
TIGeR-PaC
The Phase 3 TIGeR-PaC trial evaluates RenovoCath-mediated intra-arterial gemcitabine in locally advanced pancreatic cancer. Overall survival is the principal registrational objective, and successful results could support a future NDA.
Future catalysts
- Completion of the Phase 3 TIGeR-PaC trial in the first half of 2027.
- Topline results from TIGeR-PaC in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of RenovoRx (RNXT)?
RenovoRx (RNXT) most recently closed at 1.20 USD, a -14.29% move versus the previous session.
What is the market cap of RenovoRx (RNXT)?
RenovoRx currently has a market capitalization of 41.1M USD on BioPharmSignal.
What does RenovoRx do?
Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure. Its Trans-Arterial Micro-Perfusion platform combines a device with a targeted treatment protocol. RenovoCath RenovoCath is an FDA-cleared dual-balloon infusion catheter designed to...
On which exchange is RNXT stock listed?
RenovoRx (RNXT) is associated with NASDAQ, United States, Biopharma.
What is Targeted?
Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure.
Which conditions is RenovoRx targeting with Targeted?
RenovoRx is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does RenovoRx describe recent progress with Targeted?
Completion of the Phase 3 TIGeR-PaC trial in the first half of 2027. Topline results from TIGeR-PaC in the second half of 2027.
What is Intra-Arterial?
Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure.